Skip to main content
MEDICALSYSTEM BIOTECHNOLOGY CO., LTD logo

MEDICALSYSTEM BIOTECHNOLOGY CO., LTD — Investor Relations & Filings

Ticker · 300439 ISIN · CNE100001Z25 LEI · 3003007XTAWFVR8ASC23 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,715 across all filing types
Latest filing 2025-09-04 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300439

About MEDICALSYSTEM BIOTECHNOLOGY CO., LTD

https://www.nbmksw.com

MedicalSystem Biotechnology Co., Ltd. specializes in the research, development, production, and distribution of in vitro diagnostic (IVD) products. The company offers a comprehensive portfolio that includes biochemical reagents, chemiluminescence immunoassay systems, molecular diagnostic kits, and point-of-care testing (POCT) solutions. Its product line covers a wide range of clinical applications such as liver function, kidney function, blood lipids, and cardiovascular markers. MedicalSystem is recognized for its integrated business model, which combines the manufacturing of high-quality diagnostic instruments with a vast array of compatible reagents. Additionally, the company provides third-party medical laboratory services to healthcare institutions. By focusing on technological innovation and standardized production, MedicalSystem supports clinical laboratories in achieving accurate and efficient diagnostic results for improved patient care.

Recent filings

Filing Released Lang Actions
关于控股子公司取得医疗器械注册证的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Meikang Biotechnology Co., Ltd. regarding its controlling subsidiary obtaining medical device registration certificates issued by the Jiangxi Provincial Drug Administration. It details the registration certificate numbers, validity periods, product names, and intended uses. The document also discusses the potential impact on the company's business and includes a risk warning. There are no financial statements, earnings data, or detailed financial analysis present. The document is short (1366 characters) and serves as an official announcement of a regulatory approval related to product registration rather than a financial report or management discussion. It does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about a significant company development that does not fit other specific categories.
2025-09-04 Chinese
2025年半年度非经营性资金占用及其他关联资金往来情况汇总表
Interim / Quarterly Report Classification · 95% confidence The document is a detailed financial summary table titled '2025 Half-Year Non-Operating Fund Occupation and Other Related Fund Transactions Summary Table' for a company, including specific financial data for the first half of 2025. It contains actual financial figures and accounting details for the period January to June 2025. The document length is 3040 characters, which is relatively short but contains substantive financial data rather than just an announcement or certification. The content corresponds to a half-year financial report or interim report rather than a full annual report or other types of filings. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2025
2025-08-28 Chinese
2025年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "美康生物科技股份有限公司 2025 年半年度报告全文" which translates to "Medical System Biotechnology Co., Ltd. 2025 Semi-Annual Report Full Text." It explicitly states it is a half-year report covering the period from January 1, 2025 to June 30, 2025. The content includes detailed financial data, management discussion and analysis, company overview, business segments, financial indicators, and other comprehensive information typical of an interim or quarterly report. The document length is about 15,000 characters, indicating it is a full report rather than a brief announcement. There is no indication that this is an announcement of a report publication or a certification letter. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2025
2025-08-28 Chinese
关于增加2025年度日常关联交易预计的公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement by 美康生物科技股份有限公司 regarding an increase in the estimated amount of daily related-party transactions for the fiscal year 2025. It details the nature of these transactions, the parties involved, pricing principles, approvals by the board and supervisory committees, and compliance with relevant stock exchange rules. The document is not a financial report, audit, or earnings release but rather a regulatory announcement about related-party transactions and their expected amounts. It does not contain financial statements or detailed financial analysis but focuses on governance and compliance aspects of related-party dealings. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such compliance and disclosure announcements that do not fit other specific categories.
2025-08-28 Chinese
2025年半年度募集资金存放与使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report from 美康生物科技股份有限公司 regarding the use and management of funds raised through a specific stock issuance. It includes detailed financial figures about the amount raised, usage over multiple years, current balances, and compliance with regulatory requirements. The document references regulatory rules related to fundraising and fund management, and it is titled as a "专项报告" (special report) on the half-year usage of raised funds for 2025. It contains actual financial data, project progress, and investment details. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital usage. The document is not an announcement of a report but the report itself, and it is not an annual or interim financial report, nor an audit or earnings release. Therefore, the correct classification is CAP with high confidence.
2025-08-28 Chinese
2025年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2025 年半年度报告摘要' which translates to '2025 Semi-Annual Report Summary'. It contains detailed financial data for the half-year period, including revenue, net profit, earnings per share, and asset information. It also discusses shareholder information, changes in share capital, and corporate governance matters related to stock incentive plans. The length of the document (5233 characters) and the presence of substantive financial data and analysis confirm it is a financial report for a period shorter than a full fiscal year. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2025
2025-08-28 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.